Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Renal Transplant Infection
    Interventions:   Drug: Study Group;   Drug: Control Group
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Condition:   Transplant;Failure,Kidney
    Intervention:   Drug: Tacrolimus
    Sponsors:   Sentara Norfolk General Hospital;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Condition:   Kidney Transplant
    Intervention:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
    Sponsors:   Temple University;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Kidney Transplant;   Renal Transplant Recipients
    Interventions:   Biological: DCreg: 0.5 million cells/kg+SOC;   Biological: DCreg: 1.2 million cells/kg+SOC;   Biological: DCreg:2.5 to 5.0 million cells/kg+SOC
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   University of Pittsburgh
    Not yet recruiting

  • Condition:   End Stage Renal Disease
    Interventions:   Drug: Envarsus;   Drug: Tacrolimus
    Sponsors:   University of Kansas Medical Center;   Veloxis Pharmaceuticals
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   GVHD;   Hematologic Neoplasms
    Interventions:   Drug: Cyclophosphamide;   Drug: abatacept;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsors:   Dimitrios Tzachanis, MD PhD;   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
    Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft-versus-host-disease;   GVHD;   GVHD, Acute
    Interventions:   Drug: BMS-986004;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Heart Transplant
    Interventions:   Biological: tocilizumab;   Biological: Placebo;   Drug: Standard of Care Triple IS
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Condition:   Kidney Transplantation
    Intervention:   Drug: Belimumab
    Sponsors:   University of Wisconsin, Madison;   GlaxoSmithKline;   American College of Surgeons
    Recruiting

  • Condition:   Kidney Transplant; Complications
    Interventions:   Drug: Once daily immunosuppression regimen;   Drug: Twice daily immunosuppression regimen
    Sponsors:   Washington University School of Medicine;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Liver Transplant;   Kidney Transplant
    Interventions:   Other: PPM-based Computation Assisted Drug Dosing;   Drug: Tacrolimus
    Sponsors:   University of Florida;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg-CSB;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Conditions:   Renal Transplant Rejection;   Kidney Transplant Failure and Rejection
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet;   Drug: Tacrolimus
    Sponsors:   Columbia University;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Kidney Transplant; Complications;   Toxicity;   Drug Toxicity;   Neurotoxicity
    Interventions:   Drug: Envarsus;   Drug: IR Tacrolimus
    Sponsors:   University of California, Davis;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pediatric ALL
    Intervention:   Drug: Standard of care drug
    Sponsor:   Duke University
    Recruiting

  • Conditions:   Kidney Transplant; Complications;   Kidney Transplant Failure and Rejection
    Interventions:   Drug: Envarsus;   Drug: Tacrolimus
    Sponsors:   California Institute of Renal Research;   Balboa Institute of Transplantation;   University of California, San Diego
    Recruiting

  • Conditions:   Renal Transplantation;   Mesenchymal Stem Cells
    Interventions:   Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion;   Other: Normal Saline (Placebo) Infusion
    Sponsors:   Ahmed Osama Gaber, MD;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Condition:   Kidney Transplant; Complications
    Intervention:   Drug: Tacrolimus, Extended Release, (Envarsus Xr)
    Sponsor:   Yale University
    Recruiting

  • Condition:   End Stage Liver Disease
    Interventions:   Drug: Tacrolimus;   Drug: Everolimus
    Sponsors:   University of Kansas Medical Center;   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Myelofibrosis
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Post Liver Transplant
    Interventions:   Drug: EnvarsusXR;   Drug: Tacrolimus
    Sponsors:   Albert Einstein Healthcare Network;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Lung Transplant Rejection;   Antibody-mediated Rejection
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: ATG;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone;   Drug: Prednisone
    Sponsors:   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Kidney Transplant Rejection
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus];   Other: Plasma Exchange and IVIG (Intravenous Immunoglobulin )
    Sponsors:   University of Colorado, Denver;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Heart Transplant Rejection;   Graft Failure;   Compliance, Patient
    Intervention:   Drug: Envarsus
    Sponsor:   Baylor Research Institute
    Recruiting

  • Conditions:   Pediatric Heart Transplantation;   Immunosuppression;   Chronic Kidney Diseases;   Cardiac Allograft Vasculopathy;   Heart Transplant Failure and Rejection;   Post-transplant Lymphoproliferative Disorder;   Heart Transplant Infection
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsors:   Boston Children’s Hospital;   Stanford University;   United States Department of Defense
    Recruiting

  • Condition:   End Stage Renal Disease
    Interventions:   Drug: Tacrolimus;   Drug: Envarsus XR
    Sponsors:   Roberto Gedaly;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   End Stage Renal Disease;   Rejection of Renal Transplant
    Interventions:   Drug: Tacrolimus;   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]
    Sponsor:   Lorenzo Gallon
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Renal Transplant Patients
    Intervention:   Drug: Envarsus XR
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Kidney Transplantation;   Renal Transplantation;   Grafting, Kidney
    Interventions:   Drug: Envarsus XR;   Drug: Tacrolimus
    Sponsors:   Meghan Pearl, MD;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Condition:   Disorder Related to Renal Transplantation
    Intervention:   Drug: Tacrolimus XR (Envarsus)
    Sponsors:   University of Illinois at Chicago;   Veloxis Pharmaceuticals
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Itacitinib;   Drug: Calcineurin inhibitor
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Immune Tolerance
    Interventions:   Procedure: Immune tolerance after kidney transplant;   Drug: Donor blood stem cells and T cells
    Sponsors:   Samuel Strober;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Disorder;   Hemoglobinopathies;   Thalassemia;   Anemia, Sickle Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Rabbit anti-thymocyte globulin;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
    Sponsors:   City of Hope Medical Center;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Filgrastim;   Drug: Mycophenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   Bayer
    Recruiting

  • Conditions:   Urologic Injuries;   Genital Diseases, Male;   Amputation
    Interventions:   Procedure: Penile Transplant;   Biological: Monoclonal Antibody (Humanized Anti-CD52);   Drug: Tacrolimus
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Conditions:   Hyperkalemia;   Kidney Transplant
    Intervention:   Drug: Patiromer
    Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
    Recruiting

  • Condition:   End Stage Renal Disease
    Intervention:   Drug: Tacrolimus Extended Release Oral Capsule
    Sponsors:   Cedars-Sinai Medical Center;   Astellas Pharma Inc
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Age-Related Macular Degeneration
    Interventions:   Drug: ASP7317;   Other: Placebo;   Drug: tacrolimus;   Drug: mycophenolate mofetil (MMF)
    Sponsor:   Astellas Institute for Regenerative Medicine
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG;   Radiation: Total Marrow Irradiation;   Procedure: Stem Cell Product Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Condition:   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Sickle Cell Disease;   Bone Marrow Failure Syndromes;   Metabolic Disorders;   Immunologic Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: RIC regimen;   Drug: GVHD prophylaxis regimen
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: Busulfan;   Drug: Rituximab;   Drug: ATG;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation;   Procedure: Cord Blood Transplant;   Drug: Mycofenolate mofetil;   Drug: Tacrolimus;   Drug: Filgrastim-sndz;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Mesoblast, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
    Interventions:   Drug: Blinatumomab;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Amgen
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Renal Transplant
    Intervention:   Drug: Tacrolimus
    Sponsor:   University of North Carolina, Chapel Hill
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: Tacrolimus;   Drug: Vedolizumab;   Other: Placebo
    Sponsors:   Medical College of Wisconsin;   Takeda
    Recruiting

  • Condition:   Renal Transplant Recipients
    Intervention:   Drug: ENVARSUS®
    Sponsor:   Georgetown University
    Recruiting

  • Condition:   Immunosuppression
    Interventions:   Drug: Tacrolimus;   Drug: Prednisone;   Drug: Mycophenolate mofetil;   Drug: Everolimus
    Sponsor:   Medical University of South Carolina
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft Vs Host Disease;   GVHD
    Interventions:   Drug: Pacritinib;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   CTI BioPharma
    Recruiting

  • Conditions:   Kidney Transplantation;   Focal Segmental Glomerulosclerosis (FSGS)
    Interventions:   Drug: Bleselumab;   Drug: Basiliximab;   Drug: Mycophenolate Mofetil (MMF);   Drug: Tacrolimus Capsules;   Drug: Methylprednisone;   Drug: Prednisone
    Sponsors:   Astellas Pharma Global Development, Inc.;   Kyowa Hakko Kirin Co., Ltd
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Condition:   Renal Transplant Rejection
    Interventions:   Drug: Prograf;   Drug: Tacrolimus
    Sponsors:   University of California, Los Angeles;   Food and Drug Administration (FDA)
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Liver Transplantation
    Intervention:   Drug: Tacrolimus Withdrawal and Everolimus Monotherapy
    Sponsors:   Northwestern University;   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program
    Recruiting

  • Conditions:   HIV Infections;   Kidney Diseases
    Interventions:   Drug: Maraviroc;   Drug: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Kidney Transplant;   Adult Living Donor Kidney Transplant Recipients;   Renal Transplant;   Living Kidney Donor
    Interventions:   Biological: Polyclonal Regulatory T Cells;   Biological: Donor-Alloantigen-Reactive Regulatory T Cells;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Procedure: Biopsy, Kidney;   Procedure: Blood Draw;   Procedure: Leukapheresis;   Procedure: IS regimen conversion
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Heart Failure
    Intervention:   Drug: tacrolimus extended release
    Sponsor:   Newark Beth Israel Medical Center
    Recruiting

  • Conditions:   Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
    Interventions:   Drug: PLX3397;   Drug: Sirolimus
    Sponsors:   Gulam Manji;   Plexxikon
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Kidney Transplant
    Interventions:   Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Condition:   Solid Tumor
    Interventions:   Drug: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Valproic Acid;   Drug: Temsirolimus
    Sponsors:   Miller Children's & Women's Hospital Long Beach;   Children’s Hospital of Orange County
    Recruiting

  • Conditions:   Amputation;   Wounds and Injuries;   Amputation, Traumatic;   Urologic Surgical Procedures, Male;   Amputation, Traumatic/Surgery;   Penis/Transplantation;   Penis/Surgery;   Penis/Injuries
    Interventions:   Procedure: Penile Transplant;   Biological: Monoclonal Antibody (Humanized Anti-CD52);   Drug: Tacrolimus
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Abdominal Wall Defect
    Interventions:   Procedure: abdominal wall transplantation;   Drug: Immunosuppressive Agents
    Sponsor:   Brigham and Women's Hospital
    Recruiting

  • Conditions:   Acute Leukemia;   Myelodysplasia
    Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Failure, Chronic;   Renal Insufficiency
    Interventions:   Drug: Belatacept;   Drug: ATG;   Drug: Rituximab;   Radiation: Total Body Irradiation;   Radiation: Thymic Irradiation;   Procedure: Combined Bone Marrow/Kidney Transplantation
    Sponsor:   Massachusetts General Hospital
    Recruiting

  • Conditions:   Kidney; Complications, Allograft;   Transplantation Infection
    Intervention:   Drug: Immunosuppressive Agents
    Sponsor:   Loma Linda University
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Transplant; Failure, Kidney;   EBV
    Interventions:   Drug: belatacept;   Drug: Tacrolimus;   Drug: MPA
    Sponsors:   Lorenzo Gallon;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Liver Transplantation
    Interventions:   Biological: Anti-Thymocyte Globulin - Rabbit;   Biological: darTreg Infusion;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Anti-Infective Prophylaxis;   Procedure: Leukapheresis;   Procedure: Blood draws;   Procedure: Liver biopsies;   Procedure: Liver transplantation
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   Multiple Myeloma;   Amyloidosis
    Interventions:   Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
    Sponsor:   Massachusetts General Hospital
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Hematologic Malignancies;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis;   Myeloproliferative Syndrome
    Interventions:   Radiation: total marrow irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: myeloid progenitor cell transplantation;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Myfortic;   Drug: CellCept;   Drug: Imuran
    Sponsor:   Baylor Research Institute
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Condition:   Orthotopic Liver Transplant
    Interventions:   Drug: Everolimus;   Drug: Standard Tacrolimus
    Sponsor:   Tomoaki Kato
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Facial Injuries;   Traumatic Wounds and Injuries;   Craniofacial Injuries;   Craniofacial Defects
    Intervention:   Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Alloreactive NK infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   CML Program Project Grant
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
    Intervention:   Genetic: umbilical cord blood (UCB)
    Sponsor:   West Virginia University
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Biological: GVAX;   Biological: Placebo Vaccine;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Lymphoma
    Interventions:   Drug: Gemcitabine;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Anti-Thymocyte Globulin;   Drug: Rituximab;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoma;   Leukemia
    Interventions:   Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine monophosphate;   Drug: Melphalan;   Procedure: NK Infusion;   Procedure: CB Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Rituximab;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   American Cancer Society, Inc.;   CLL Global Research Foundation
    Recruiting

  • Condition:   Diabetes Mellitus, Type 1
    Interventions:   Biological: Allogenic islet cells (human, U. Chicago);   Procedure: Intraportal infusion of islet cells
    Sponsor:   University of Chicago
    Recruiting

  • Conditions:   Amputation, Traumatic;   Wounds and Injuries;   Hand Injuries
    Interventions:   Procedure: Deceased donor hand transplantation;   Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
    Sponsors:   Johns Hopkins University;   Armed Forces Institute of Regenerative Medicine;   U.S. Army Medical Research Acquisition Activity
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Drug: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Condition:   Type 1 Diabetes Mellitus
    Intervention:   Drug: Islets of Langerhans transplantation
    Sponsor:   CellTrans Inc.
    Recruiting

  • Condition:   Atopic Dermatitis
    Intervention:   Drug: Pimecrolimus
    Sponsors:   Valeant Pharmaceuticals International, Inc.;   Clinical Research Computing Unit (University of Pennsylvania)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting


PaidClinicalTrials.orgPaidClinicalTrials.org